MRE11 as a predictive biomarker of outcome following radiotherapy in bladder cancer
<br/><strong>Purpose: </strong>Organ-confined muscle-invasive bladder cancer is treated with cystectomy or bladder preservation techniques, including radiation therapy. There are currently no biomarkers to inform management decisions and aid patient choice. Previously we showed hig...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Elsevier
2019
|
| _version_ | 1826293806719303680 |
|---|---|
| author | Walker, AK Karaszi, K Valentine, H Strauss, VY Choudhury, A McGill, S Wen, K Brown, MD Ramani, V Bhattarai, S Teo, MTW Yang, L Myers, KA Deshmukh, N Denley, H Browning, L Love, SB Iyer, G Clarke, NW Hall, E Huddart, R James, ND Hoskin, PJ West, CML Kiltie, AE |
| author_facet | Walker, AK Karaszi, K Valentine, H Strauss, VY Choudhury, A McGill, S Wen, K Brown, MD Ramani, V Bhattarai, S Teo, MTW Yang, L Myers, KA Deshmukh, N Denley, H Browning, L Love, SB Iyer, G Clarke, NW Hall, E Huddart, R James, ND Hoskin, PJ West, CML Kiltie, AE |
| author_sort | Walker, AK |
| collection | OXFORD |
| description | <br/><strong>Purpose: </strong>Organ-confined muscle-invasive bladder cancer is treated with cystectomy or bladder preservation techniques, including radiation therapy. There are currently no biomarkers to inform management decisions and aid patient choice. Previously we showed high levels of MRE11 protein, assessed by immunohistochemistry (IHC), predicted outcome after radiation therapy, but not cystectomy. Therefore, we sought to develop the MRE11 IHC assay for clinical use and define its relationship to clinical outcome in samples from 2 major clinical trials.<br/><strong>Methods and Materials: </strong>Samples from the BCON and BC2001 randomized controlled trials and a cystectomy cohort were stained using automated IHC methods and scored for MRE11 in 3 centers in the United Kingdom.<br/><strong>Results: </strong>Despite step-wise creation of scoring cards and standard operating procedures for staining and interpretation, there was poor intercenter scoring agreement (kappa, 0.32; 95% confidence interval, 0.17-0.47). No significant associations between MRE11 scores and cause-specific survival were identified in BCON (n = 132) and BC2001 (n = 221) samples. Reoptimized staining improved agreement between scores from BCON tissue microarrays (n = 116), but MRE11 expression was not prognostic for cause-specific survival.<br/><strong>Conclusions: </strong>Manual IHC scoring of MRE11 was not validated as a reproducible biomarker of radiation-based bladder preservation success. There is a need for automated quantitative methods or a reassessment of how DNA-damage response relates to clinical outcomes. |
| first_indexed | 2024-03-07T03:35:51Z |
| format | Journal article |
| id | oxford-uuid:bc3f1902-f103-4f02-b827-850c972c9065 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T03:35:51Z |
| publishDate | 2019 |
| publisher | Elsevier |
| record_format | dspace |
| spelling | oxford-uuid:bc3f1902-f103-4f02-b827-850c972c90652022-03-27T05:23:04ZMRE11 as a predictive biomarker of outcome following radiotherapy in bladder cancerJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:bc3f1902-f103-4f02-b827-850c972c9065EnglishSymplectic Elements at OxfordElsevier2019Walker, AKKaraszi, KValentine, HStrauss, VYChoudhury, AMcGill, SWen, KBrown, MDRamani, VBhattarai, STeo, MTWYang, LMyers, KADeshmukh, NDenley, HBrowning, LLove, SBIyer, GClarke, NWHall, EHuddart, RJames, NDHoskin, PJWest, CMLKiltie, AE<br/><strong>Purpose: </strong>Organ-confined muscle-invasive bladder cancer is treated with cystectomy or bladder preservation techniques, including radiation therapy. There are currently no biomarkers to inform management decisions and aid patient choice. Previously we showed high levels of MRE11 protein, assessed by immunohistochemistry (IHC), predicted outcome after radiation therapy, but not cystectomy. Therefore, we sought to develop the MRE11 IHC assay for clinical use and define its relationship to clinical outcome in samples from 2 major clinical trials.<br/><strong>Methods and Materials: </strong>Samples from the BCON and BC2001 randomized controlled trials and a cystectomy cohort were stained using automated IHC methods and scored for MRE11 in 3 centers in the United Kingdom.<br/><strong>Results: </strong>Despite step-wise creation of scoring cards and standard operating procedures for staining and interpretation, there was poor intercenter scoring agreement (kappa, 0.32; 95% confidence interval, 0.17-0.47). No significant associations between MRE11 scores and cause-specific survival were identified in BCON (n = 132) and BC2001 (n = 221) samples. Reoptimized staining improved agreement between scores from BCON tissue microarrays (n = 116), but MRE11 expression was not prognostic for cause-specific survival.<br/><strong>Conclusions: </strong>Manual IHC scoring of MRE11 was not validated as a reproducible biomarker of radiation-based bladder preservation success. There is a need for automated quantitative methods or a reassessment of how DNA-damage response relates to clinical outcomes. |
| spellingShingle | Walker, AK Karaszi, K Valentine, H Strauss, VY Choudhury, A McGill, S Wen, K Brown, MD Ramani, V Bhattarai, S Teo, MTW Yang, L Myers, KA Deshmukh, N Denley, H Browning, L Love, SB Iyer, G Clarke, NW Hall, E Huddart, R James, ND Hoskin, PJ West, CML Kiltie, AE MRE11 as a predictive biomarker of outcome following radiotherapy in bladder cancer |
| title | MRE11 as a predictive biomarker of outcome following radiotherapy in bladder cancer |
| title_full | MRE11 as a predictive biomarker of outcome following radiotherapy in bladder cancer |
| title_fullStr | MRE11 as a predictive biomarker of outcome following radiotherapy in bladder cancer |
| title_full_unstemmed | MRE11 as a predictive biomarker of outcome following radiotherapy in bladder cancer |
| title_short | MRE11 as a predictive biomarker of outcome following radiotherapy in bladder cancer |
| title_sort | mre11 as a predictive biomarker of outcome following radiotherapy in bladder cancer |
| work_keys_str_mv | AT walkerak mre11asapredictivebiomarkerofoutcomefollowingradiotherapyinbladdercancer AT karaszik mre11asapredictivebiomarkerofoutcomefollowingradiotherapyinbladdercancer AT valentineh mre11asapredictivebiomarkerofoutcomefollowingradiotherapyinbladdercancer AT straussvy mre11asapredictivebiomarkerofoutcomefollowingradiotherapyinbladdercancer AT choudhurya mre11asapredictivebiomarkerofoutcomefollowingradiotherapyinbladdercancer AT mcgills mre11asapredictivebiomarkerofoutcomefollowingradiotherapyinbladdercancer AT wenk mre11asapredictivebiomarkerofoutcomefollowingradiotherapyinbladdercancer AT brownmd mre11asapredictivebiomarkerofoutcomefollowingradiotherapyinbladdercancer AT ramaniv mre11asapredictivebiomarkerofoutcomefollowingradiotherapyinbladdercancer AT bhattarais mre11asapredictivebiomarkerofoutcomefollowingradiotherapyinbladdercancer AT teomtw mre11asapredictivebiomarkerofoutcomefollowingradiotherapyinbladdercancer AT yangl mre11asapredictivebiomarkerofoutcomefollowingradiotherapyinbladdercancer AT myerska mre11asapredictivebiomarkerofoutcomefollowingradiotherapyinbladdercancer AT deshmukhn mre11asapredictivebiomarkerofoutcomefollowingradiotherapyinbladdercancer AT denleyh mre11asapredictivebiomarkerofoutcomefollowingradiotherapyinbladdercancer AT browningl mre11asapredictivebiomarkerofoutcomefollowingradiotherapyinbladdercancer AT lovesb mre11asapredictivebiomarkerofoutcomefollowingradiotherapyinbladdercancer AT iyerg mre11asapredictivebiomarkerofoutcomefollowingradiotherapyinbladdercancer AT clarkenw mre11asapredictivebiomarkerofoutcomefollowingradiotherapyinbladdercancer AT halle mre11asapredictivebiomarkerofoutcomefollowingradiotherapyinbladdercancer AT huddartr mre11asapredictivebiomarkerofoutcomefollowingradiotherapyinbladdercancer AT jamesnd mre11asapredictivebiomarkerofoutcomefollowingradiotherapyinbladdercancer AT hoskinpj mre11asapredictivebiomarkerofoutcomefollowingradiotherapyinbladdercancer AT westcml mre11asapredictivebiomarkerofoutcomefollowingradiotherapyinbladdercancer AT kiltieae mre11asapredictivebiomarkerofoutcomefollowingradiotherapyinbladdercancer |